Background: Most comparative clinical trials are designed to assess the treatment effect for efficacy endpoints, with less emphasis on the analysis of safety outcomes.
Chen C.L.H. (8523633) +4 more
core +1 more source
Interventions for visual field defects after stroke: a systematic review. [PDF]
Etter et hjerneslag er det mange som mister deler av synsfeltet. Det er vanlig å miste halvparten av synsfeltet (høyre eller venstre) på begge øynene. Tiltak som har blitt forsøkt er å gjenvinne hele eller deler av synsfeltet (restitusjon), kompensere ...
Myrhaug, Hilde Tinderholt +1 more
core
Ischemic Stroke: New Insights from Risk Factors, Mechanisms and Outcomes. [PDF]
Venketasubramanian N.
europepmc +1 more source
MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study. [PDF]
Pakdaman H +9 more
europepmc +1 more source
Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol. [PDF]
Pilipenko P +7 more
europepmc +1 more source
Clinical Study The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients
Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (n = 30; 9 female) for three ...
Alejandro C Baroque Ii +3 more
core
Effect of MLC901 on MIR30C-5P expression, TGF-Β expression, VEGF receptor expression, degree of axon demyelination and changes in neuropathic pain behaviour in experimental animals experiencing neuropathic pain with circumferential spinal stenosis method. [PDF]
Priyanto B +4 more
europepmc +1 more source
New evidence for the pharmacological intervention promoting neurorecovery after stroke: results from the joint EAN-EFNR guidelines. [PDF]
Muresanu D, Cretoiu D.
europepmc +1 more source
Pharmacological Treatment of Acute Ischemic Stroke [PDF]
Cohen-Minian, Yael +3 more
core +2 more sources

